About the Chinese Journal of Cancer Biotherapy

The Chinese Journal of Cancer Biotherapy is a professional academic journal in the field of cancer biotherapy, jointly sponsored by the Chinese Society for Immunology and the Chinese Anti-Cancer Association. The journal is recognized as a Chinese Core Journal, a Chinese Science and Technology Core Journal, and a Source Journal for Chinese Scientific and Technical Papers and Citations. Founded in 1994, the journal is published monthly in A4 format, with 105 pages per issue, and is distributed both in China and internationally.

The Chinese Journal of Cancer Biotherapy is the only academic journal in China dedicated specifically to the field of cancer biotherapy. Its mission is to promote academic exchange, advance scientific research, support clinical practice, contribute to the development of cancer prevention and treatment, and improve public health. The journal provides comprehensive coverage of the latest achievements and academic developments in both basic research and clinical applications of cancer biotherapy in China. It also actively communicates relevant policies and development strategies in the field and provides timely updates on the latest advances in cancer biotherapy worldwide.

The journal publishes articles in a wide range of sections, including Editorials, Academician Forums, Expert Forums, Rapid Communications, Basic Research, Clinical Research, Techniques and Methods, Academic Debates, Reviews, Special Lectures, and Science and Technology Updates. Its primary readership includes researchers and clinicians engaged in cancer prevention and treatment, faculty members and students at medical universities and colleges, and scientists and professionals in related disciplines.

The Editor-in-Chief of the Chinese Journal of Cancer Biotherapy is Professor Cao Xuetao, Member of the Chinese Academy of Engineering, Honorary President of the Chinese Society for Immunology, Chief Technical Scientist of the National Major Project for New Drug Development, Chairman of the Academic Committee of the Chinese Academy of Medical Sciences, and Chairman of the Academic Committee of the State Key Laboratory of Immunity and Inflammation.

The Editorial Board brings together many distinguished experts from the Chinese Society for Immunology and the Chinese Anti-Cancer Association. Among its members are 13 academicians of the Chinese Academy of Sciences and the Chinese Academy of Engineering: Bian Xiuwu, Cao Xuetao, Chen Xiaoping, Chen Zhinan, Huang Xiaojun, Li Zhaoshen, Lin Dongxin, Ma Ding, Tian Zhigang, Wang Fusheng, Wei Yuquan, Yu Jinming, and Zhan Qimin. The Board also includes directors of four national key laboratories: Professor Zhan Qimin, Director of the State Key Laboratory of Molecular Oncology; Professor Chen Zhinan, Director of the National Key Laboratory of New Drug Discovery and Development; Professor Wei Yuquan, Director of the National Key Laboratory of Biotherapy; and Professor Cao Xuetao, Director of the National Key Laboratory of Immunity and Inflammation. A number of chief scientists and project experts from China's national “863” and “973” programs also serve on the Editorial Board.

The strong academic expertise of the Editorial Board provides substantial scholarly guidance for the development of the journal and contributes actively to manuscript solicitation, peer review, and the journal's responsible editor system.

The Chinese Journal of Cancer Biotherapy has been indexed or covered by several international databases and abstracting services, including Chemical Abstracts (CA), Cambridge Scientific Abstracts (CSA), Ulrich's International Periodicals Directory (Ulrich IPD), EMBASE, CABI, and Index Copernicus (IC). The journal is also associated with international DOI registration and Crossref.

In China, the journal has been indexed or included in major databases and abstracting services such as the Chinese Scientific and Technical Papers and Citations Database (CSTPCD), Chinese Science Citation Database (CSCD), Chinese Academic Journal Comprehensive Evaluation Database (CAJCED), Chinese Biomedical Literature Database (CBMdisc), Chinese Medical Current Contents (CMCC), A Guide to the Core Journals of China, Chinese Academic Journal Abstracts, Chinese Medical Abstracts—Oncology, Chinese Biological Abstracts, and the World Journal Clout Index (WJCI) Report, among others. The journal's academic visibility and dissemination of scientific information have continued to expand both in China and internationally.

The Chinese Journal of Cancer Biotherapy places great emphasis on the originality and scientific quality of published research. Through systematic editorial planning, careful topic selection, and active manuscript solicitation, the journal strives to attract high-quality papers addressing emerging and cutting-edge topics in cancer biotherapy.

All manuscripts are subject to peer review by independent experts, and the journal follows a rigorous quality-control process in selecting papers for publication. Most of the articles published in the journal originate from national, provincial, and ministerial-level key laboratories and leading oncology research institutions in China.

The journal focuses particularly on new findings, theories, technologies, and experience arising from basic and clinical research in six major areas of cancer biotherapy: cell therapy, immunotherapy, monoclonal antibody therapy, cancer vaccines, gene therapy, and small-molecule targeted therapy. For eight consecutive years, more than 70% of the papers published in the journal have reported research supported by scientific research grants.

The journal also places a strong emphasis on the timely dissemination of academic research. The average period from manuscript submission to publication is approximately six months. Manuscripts reporting major innovations or first reports of important findings may be published rapidly as Rapid Communications, generally within one to two months.

The journal frequently organizes groups of articles to provide systematic and in-depth coverage of specific topics. Each issue also invites prominent oncology experts from China and abroad to contribute editorials and forum articles. In the Fifth Outstanding Journal Paper Selection organized by the China Association for Science and Technology, the journal received awards for four papers, the highest number among the 426 participating journals. In recent journal standardization reviews conducted by the relevant national publishing authority and journal evaluations organized by the China Association for Science and Technology, the journal was rated respectively as a “Grade A Journal” and a “Journal with Excellent Content.” The journal enjoys a strong academic reputation and influence within the medical community in China.

The Chinese Journal of Cancer Biotherapy strictly follows national standards and professional guidelines for academic editing and publishing and attaches great importance to the standardization and professionalization of journal publishing. The Editorial Office implements a rigorous system of multiple rounds of proofreading and final editorial review to maintain consistently high editorial and publication quality.

The journal operates an independent website at www.biother.cn and adopts an Open Access (OA) publishing model. It has also established an online manuscript submission, peer-review, editing, and production system, which has significantly improved the efficiency and timeliness of manuscript processing and publication.

Developing the Chinese Journal of Cancer Biotherapy into a high-quality journal with greater international visibility and influence remains a long-term and unwavering goal. The Editorial Office will continue to advance the journal through sustained effort and innovation and to provide high-quality academic publishing services in appreciation of the continued support of researchers and professionals engaged in cancer prevention and treatment.

Contact Information

Address: Immunology Building, 800 Xiangyin Road, Shanghai 200433, China
Postal Code: 200433
Telephone: +86-21-81871002, Ext. 22
Website: www.biother.cn
Email: cjcb@biother.cn
Manuscript Status Inquiry: cjcb1994@126.com